Phase 2 Study Assessing the Clinical Activity and Safety of Obecabtagene Autoleucel as a Consolidation in Patients With Newly Diagnosed High-risk B-cell Acute Lymphocytic Leukemia (ALL)

The goal of this clinical research study is to learn if obecabtagene autoleucel (obe-cel) can help to control newly diagnosed, high-risk B-cell ALL when given as consolidation therapy. Consolidation therapy is given after the first phase of treatment.

Start Date01 Dec 2025

Sponsor / Collaborator

The University of Texas MD Anderson Cancer Center

[+1]

NCT07053800

/ Not yet recruitingPhase 2

A Single-Arm, Open-Label, Phase II Study to Determine the Safety and Efficacy of Obecabtagene Autoleucel (Obe-cel) in Participants With Severe, Refractory Systemic Lupus Erythematosus With Active Lupus Nephritis

This trial aims to find out if obe-cel gets rid of harmful B cells that contribute to systemic lupus erythematosus (SLE)/lupus nephritis (LN) when available treatments have not worked (refractory). The trial includes only 1 group of patients (single arm), including teenage and adult patients aged 12 to 65 years. The objective is to look for benefits of obe-cel in making signs of LN completely disappear (remission) at 6 months after treatment in patients with severe, active LN. The trial will also look for other benefits of obe-cel for up to 24 months after treatment, including the percentage of patients who respond to obe-cel treatment, SLE/LN activity, time to and length of remission, and quality of life. The trial will also assess how long obe-cel stays in the body and the safety of obe-cel.

Start Date01 Sep 2025

Sponsor / Collaborator

Autolus Ltd.

[+1]

NCT07139743

/ RecruitingPhase 1

A Single-arm, Open-label, Phase I Study to Determine the Safety, Tolerability, and Preliminary Efficacy of Obe-cel in Participants With Refractory Progressive Forms of Multiple Sclerosis

The main purpose of this study is to evaluate if obe-cel is safe or causes any side effects in adults with refractory progressive MS. The study also plans to assess if obe-cel can show early signs of efficacy in MS. The trial includes only 1 group of patients (single-arm). The study population comprises patients with progressive forms of MS, not responsive to highly effective therapies.
Upon confirmation of study eligibility, patients will receive fludarabine and cyclophosphamide (types of chemotherapy, used here for lymphodepletion) over 1 to 3 days in preparation for receiving a single obe-cel infusion.
Patients will be checked closely in the 28 days following obe-cel treatment. After this, patients will be monitored to evaluate safety and efficacy up to 24 months.

Start Date04 Aug 2025

Sponsor / Collaborator

Autolus Ltd.

100 Clinical Results associated with Obecabatagene autoleucel

100 Translational Medicine associated with Obecabatagene autoleucel

100 Patents (Medical) associated with Obecabatagene autoleucel

Literatures (Medical) associated with Obecabatagene autoleucel

25 Jul 2025·ANNALS OF HEMATOLOGY

Prophylactic Tocilizumab prior to infusion of CD19 CAR T-cells reduces therapy-related complications in older lymphoma patients.

Article

Author: Musa, Albulena ; Rieger, Max J ; Manz, Markus G ; Stolz, Sebastian M ; Zenz, Thorsten ; Bachofner, Adrian ; Gourri, Elise ; Bankova, Andriyana K ; Wolfensberger, Nathan ; Rösler, Wiebke ; Schneidawind, Dominik

CAR (chimeric antigen receptor) T-cell therapies have transformed treatment for relapsed and refractory B cell lymphomas (r/r BCL) and plasma cell myeloma. While real-world experiences have shown success across age groups, patients over 70 years require special attention due to therapy-related complications like cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), which can lead to adverse outcomes. This study analyzed outcomes of 26 r/r BCL patients aged ≥ 70 years treated with CAR T-cell therapy between 2019 and 2023, comparing those who received prophylactic Tocilizumab (N = 7) versus standard treatment (N = 19). The median age was 75 years, with patients having received a median of three prior therapy lines. Prophylactic Tocilizumab was given 1 h before re-transfusion of CAR T-cells. Patients receiving prophylactic Tocilizumab experienced significantly fewer therapy-related complications (p = 0.039) which were defined as one or more of the following events: severe CRS, severe ICANS, corticosteroid use, need for transfusions, treatment in a critical care unit, prolonged hospitalization and discharge to a care facility. Hospital stays in total were shorter in the Tocilizumab group (15.9 vs. 18.5 days), though not statistically significant. Progression-free and overall survival were similar between groups. The results suggest that prophylactic Tocilizumab may optimize management of older CAR T-cell patients, aligning with existing evidence regarding its prophylactic use in r/r BCL.

01 Jun 2025·Transplantation and Cellular Therapy

Awakening from REMS: ASTCT 80/20 Ongoing Recommendations for Safe Use of Chimeric Antigen Receptor T Cells

Review

Author: Mahmoudjafari, Zahra ; Kebriaei, Partow ; Locke, Frederick L ; Frigault, Matthew J ; Nikiforow, Sarah ; Perales, Miguel-Angel ; Frey, Noelle V ; Gardner, Rebecca A ; Komanduri, Krishna V

The first 6 chimeric antigen receptor T cell (CAR-T) therapies approved in the United States have Risk Evaluation Mitigation Strategies (REMS) programs mandated by the US Food and Drug Administration (FDA). REMS programs aim to ensure the safe use of CAR-T therapy through timely recognition and management of unique severe risks and toxicities that cannot be mitigated by labeling alone, such as cytokine release syndrome and neurotoxicity syndromes. At the launch of each of the first 6 products, CAR-T REMS programs mandated product-specific education and training for clinical staff, patients, and caregivers; adequate access to medications to treat expected toxicities; and reporting of toxicities either to the product manufacturer or to the FDA. Each manufacturer ensures that treatment centers comply with the REMS program for their individual product in different ways, involving time-consuming and often redundant training, testing, and audits. The American Society for Transplantation and Cellular Therapy (ASTCT) 80/20 Subcommittee convened its second workshop in June 2023, inviting approximately 70 cellular therapy stakeholders to discuss whether safety and quality workflows embedded in existing resources within the cellular therapy field could replace FDA-mandated and company-monitored REMS programs. Attendees were clinicians at large academic medical centers experienced in cellular therapy, regulators, members of accrediting bodies and professional societies, and manufacturers of immune effector cell (IEC) therapies at multiple stages of development. Discussion centered on (1) educational requirements for safe delivery and management, (2) goals and mechanisms for data reporting and to whom, and (3) what entities should oversee these quality safeguards around CAR-T administration and management. Broad support was voiced for (1) conducting training programs administered by treatment centers and/or professional societies to replace manufacturers' product training; (2) reporting standardized data points into a central, accessible repository for tracking of safety trends and identification of new signals; and (3) enabling accrediting bodies to attest to programs' quality and ongoing compliance with field safety expectations, thereby replacing intensive manufacturer initial evaluation and ongoing REMS audits. The strong consensus of the second multidisciplinary ASTCT 80/20 Workshop was that such measures would allow elimination, or at least significant reduction and simplification, of current CAR-T REMS programs. Development of educational resources and funding for data reporting outside of a mandated REMS structure were identified as critical, particularly to support treatment centers new to cellular therapy, as were ongoing collaborations with FDA and manufacturers. These consensus recommendations were shared with the FDA at the Cell Therapy Liaison Meeting and in multiple professional society meetings and other public forums with regulators, manufacturers, and FDA representatives. Recently the FDA scaled back several of the features of existing CAR-T REMS programs redundant to standard clinical practice, specifically requirements related to manufacturer-created training, product-specific testing of trained staff, and data reporting to manufacturers. The seventh commercial CAR-T product (Aucatzyl, or obecabtagene autoleucel) was the first approved without a REMS program as of November 8, 2024. Continued streamlining of already widespread CAR-T safety standards for existing and future approved CAR-T cells and other unique cellular therapy products and ensuring their adoption at new and existing treatment centers will be required to maintain and increase access to the ever-growing number of effective adoptive cellular therapies.

12 May 2025·LEUKEMIA & LYMPHOMA

Frontline immunotherapeutic combination strategies in adult B-cell acute lymphoblastic leukemia: reducing chemotherapy intensity and toxicity and harnessing efficacy

Review

Author: Haddad, Fadi G. ; Habib, Diane ; Senapati, Jayastu ; Short, Nicholas J. ; Kantarjian, Hagop ; Jabbour, Elias ; Jain, Nitin

Using immunotherapeutic agents like inotuzumab ozogamicin (InO), blinatumomab, or chimeric antigen receptor T (CAR T)-cell therapy in frontline adult B-cell acute lymphoblastic leukemia (B-ALL) therapy is promising. These agents are mostly well tolerated and have different toxicity profiles than conventional chemotherapy, enabling their combination with chemotherapy. Additionally, they have often been shown to overcome the traditional adverse ALL risk features. Recently blinatumomab was approved as part of consolidation therapy in MRD negative B-ALL; however, a significant proportion of patients had progressed or relapsed before reaching the timepoint of blinatumomab administration. Including InO/blinatumomab from induction onwards could induce earlier and deeper remissions. Modifications of dosing and administration schedules, as with the fractionated InO schedule with low-intensity chemotherapy, and subcutaneous blinatumomab, appear to reduce the toxicity and improve the anti-ALL efficacy. CAR T-cell therapies like brexucabtagene autoleucel as a consolidation approach have shown positive outcomes. The feasibility of using CAR T-cells to reduce the need for long-drawn maintenance and the need for allogeneic hematopoietic stem cell transplantation (HSCT) are questions of ongoing clinical trials. Newer generation CAR T-cell products like obecabtagene autoleucel appear as effective and safer. Better disease monitoring through next generation sequencing based measurable residual disease analysis could identify patients where treatment intensification including HSCT, or deintensification, is suitable.

News (Medical) associated with Obecabatagene autoleucel

15 Aug 2025

·www.biopharmadive.com

Precigen wins immunotherapy approval; Pfizer sickle cell drug fails trial

Today, a brief rundown of news involving Precigen and Pfizer, as well as updates from the Institute for Clinical and Economic Review, Superluminal Medicines and Generation Bio that you may have missed.The Food and Drug Administration granted full approval to a first-of-its-kind treatment for recurrent respiratory papillomatosis, a rare and potentially life-threatening condition caused by persistent HPV infections. Thursdays clearance of PrecigensPapzimeos, an immunotherapy that helps clear HPV-infected cells, was based on study results showing a little more than half of drug recipients didn't need surgery within a year of therapy. Center for Biologics Evaluation and Research director Vinay Prasad, who rejoined the FDA this week, described the approval as proof randomized trials are not always needed to approve medical products. That statement should be reassuring to biotech investors concerned about stricter regulatory standards under Prasad, wrote Cantor Fitzgerald analyst Jennifer Kim. Precigen shares rose higher Friday on the news. Ben FidlerAn experimental Pfizer drug for sickle cell disease failed to meet its goal in a Phase 3 study, the company said Friday. Testing showed that treatment with inclacumab, a drug Pfizer acquired via its 2022 buyout of Global Blood Therapeutics, failed to significantly reduce versus placebo the pain crises people with sickle cell often experience. Pfizer said it would share analyses of the data with the scientific and patient community in due course. Last year, the company pulled from market another sickle cell drug, Oxbryta, that it gained from Global Blood, citing safety concerns. The company plans to provide updates on Oxbryta and a third Global Blood drug, the experimental osivelotor, when they become available. Ned PagliaruloEli Lilly will collaborate with biotechnology startup Superluminal Medicines to develop new drugs for cardiometabolic diseases and obesity. Through the alliance, the two intend to discover and advance small molecule medicines aimed at undisclosed G protein-coupled receptor, or GPCR, targets relevant to those conditions. Lilly will receive exclusive rights to the compounds emerging from the deal, while Superluminal could get up to $1.3 billion in total payouts, including an unspecified upfront payment as well as an equity investment, the companies said Thursday. Ben FidlerAutolus Therapeutics is delaying launching its leukemia cell therapy Aucatzyl in Europe following approval there as the company evaluates potential pricing and feasibility of market entry opportunities in some countries. Launch in Germany is on hold and Autolus does not anticipate any EU sales of Aucatzyl in 2025 and 2026, the company said in its second quarter earnings report. In the U.K., where Aucatzyl has also been approved, a government cost-effectiveness monitor has initially decided not to pay for it. Autolus said it will continue to work towards a pathway for patient access to therapy in the U.K. Approved by the Food and Drug Administration in November 2024, Aucatzyl earned just shy of $30 million in sales in the first six months of 2025, all from the U.S. Jonathan GardnerGeneration Bio revealed preclinical results suggesting a delivery technology its developing can effectively send nucleic acid payloads into T cells. But the company also said this week that it may not be able to raise the funds to prove that approach works in humans and, as a result, began a strategic review that could end in a sale or merger. Generation will lay off roughly 90% of its workforce, including all of its research and development staff, by the end of October. Company shares climbed 60%, though theyve lost much of their value since the companys initial public offering in 2020. Ben Fidler '

Drug ApprovalImmunotherapyPhase 3Cell TherapyAcquisition

13 Aug 2025

·endpoints.news

Autolus says it won’t make money from its cell therapy in Europe until 2027

Despite a recent approval in Europe, Autolus Therapeutics does not expect to sell its blood cancer cell therapy in the region until 2027 and specifically noted that its German launch plans are on hold. The CD19-targeted cell therapy called Aucatzyl was greenlit by the European Commission for relapsed or refractory B cell precursor acute lymphoblastic leukemia last month, following a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) in May. However, the biotech doesn’t anticipate any European sales this year or next, as the path to market access in Europe often requires data from randomized controlled studies. This presents a challenge for therapies like its cell therapy, which were evaluated in single-arm registrational trials, Autolus CEO Christian Itin said on a Tuesday earnings call with analysts. The company’s share price $AUTL was down about 12% at market close Tuesday. Autolus said it is currently assessing “pricing and feasibility of market entry opportunities” in EU states. “We’re going to do this very methodically, going to go through country by country,” Itin said. The company has put its planned German launch on pause to allow more time for engagement with physicians, patient bodies and regulators there. Itin added that the Trump administration’s calls for a “most favored nation” approach to drug pricing in the US could also “create tension that may or may not be helpful” for Autolus’ efforts in Europe. Aucatzyl was also approved by the UK’s Medicines and Healthcare products Regulatory Agency in April. But the country’s cost-effectiveness watchdog, the National Institute for Health and Care Excellence, has made a preliminary recommendation against reimbursing the treatment. Nonetheless, the therapy is enjoying some momentum in the US, where it made $20.9 million in Q2. The figure beat Wall Street consensus estimates of $14.1 million, Jefferies analysts said. The treatment has had a “very, very positive reception” from the US medical community, Itin told analysts. Its strong “safety profile and manageability” has encouraged centers to reorder doses “very early on,” he added. Aucatzyl won FDA approval in November 2024. It is given in two doses around ten days apart and has a list price of $525,000. Autolus said it has secured Aucatzyl coverage for more than 90% of total US medical lives so far. As of Aug. 12, 46 centers across the country were administering the treatment. The biotech plans to expand to 60 or more centers by the end of the year, Itin said.

Cell TherapyDrug ApprovalImmunotherapy

31 Jul 2025

·www.businesswire.com

European Commission Approves CAR-T Therapy With Lentiviral Vectors Manufactured by AGC Biologics

MILAN--(BUSINESS WIRE)--Following news on July 21 that the European Commission has granted marketing authorization for AUCATZYL® (obecabtagene autoleucel – obe-cel), AGC Biologics’ Milan site achieved its 10th product approval from the European Medicines Agency or the U.S. Food and Drug Administration. Developed by Autolus Therapeutics, AUCATZYL® is now approved to treat adult patients (age 26 and older) in 27 European Union member states with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (r/r B-ALL). This follows the therapy’s prior authorizations from the FDA in November 2024 and the U.K. Medicines and Healthcare products Regulatory Agency in April 2025. This latest step further solidifies AGC Biologics’ Milan Cell and Gene Center of Excellence’s reputation as a global leader in the field, built on a 30-year track record of quality, reliability, and regulatory success. “This European approval for Autolus is a milestone we are thrilled to be part of. Our goal is to be the industry’s safe harbor: a trusted, friendly expert CDMO that de-risks the complex path to commercialization,” said Alberto Santagostino, CEO and President, AGC Biologics. “By ensuring a reliable supply of their vital lentiviral vector, we empower our partners to focus on patients. Congratulations to the entire Autolus team.” The partnership between Autolus and AGC Biologics Milan began in 2020, with the CDMO tasked to develop, manufacture, and supply the viral vectors for Autolus’ obe-cel CAR-T product candidate. “From the start of our partnership in 2020, through the FDA approval and now this European authorization, our collaboration with Autolus has been a model of true partnership,” said Luca Alberici, General Manager, AGC Biologics Milan. “The team’s sustained dedication and technical excellence is a direct result of our ability to work seamlessly with the Autolus team to meet the demands of commercial-scale manufacturing for a global market.” With its 30-year track record and 10 product approvals by the EMA and FDA, the AGC Biologics Milan site is a global leader with deep expertise in complex cell and gene therapy projects. The team has guided numerous products to commercial stages, manufactured hundreds of batches for clinical supply, and consistently met the highest global regulatory guidelines, quality performance metrics, and the unique complexities of technology transfers and manufacturing scale-up. To learn more about AGC Biologics’ global cell therapy services, visit www.agcbio.com/capabilities/cell-therapy, and for more on the CDMO’s viral vector offerings, visit www.agcbio.com/capabilities/viral-vector. About AGC Biologics AGC Biologics is a leading global biopharmaceutical Contract Development and Manufacturing Organization (CDMO) with a strong commitment to delivering the highest standard of service as we work side-by-side with our clients and partners, to provide friendly and expert services. We provide world-class development and manufacturing of mammalian and microbial-based therapeutic proteins, plasmid DNA (pDNA), messenger RNA (mRNA), viral vectors, and genetically engineered cells. Our global network spans the U.S., Europe, and Asia, with locations in Seattle, Washington; Boulder and Longmont, Colorado; Copenhagen, Denmark; Heidelberg, Germany; Milan, Italy; and Chiba and Yokohama, Japan. We currently employ more than 2,600 Team Members worldwide. AGC Biologics is a part of AGC Inc.’s Life Science Business. The Life Science Business runs 10+ facilities focused on biopharmaceuticals, advanced therapies, small molecule active pharmaceutical ingredients, and agrochemicals. To learn more, visit www.agcbio.com. AUCATZYL® (obecabtagene autoleucel – obe-cel) is a registered trademark of Autolus Therapeutics.

Drug ApprovalCell TherapyImmunotherapyGene Therapy

100 Deals associated with Obecabatagene autoleucel

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Pre B-cell acute lymphoblastic leukemia	United States	Autolus Ltd.	08 Nov 2024

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Recurrent B Acute Lymphoblastic Leukemia	NDA/BLA	United States	Autolus Therapeutics Plc	29 Nov 2023
Refractory B Acute Lymphoblastic Leukemia	NDA/BLA	United States	Autolus Therapeutics Plc	29 Nov 2023
Lupus Nephritis	Phase 2	-	Autolus Ltd.	01 Sep 2025
Acute Lymphoblastic Leukemia	Phase 2	United States	Autolus Ltd.	03 Jun 2020
Acute Lymphoblastic Leukemia	Phase 2	Spain	Autolus Ltd.	03 Jun 2020
Acute Lymphoblastic Leukemia	Phase 2	United Kingdom	Autolus Ltd.	03 Jun 2020
Philadelphia positive acute lymphocytic leukaemia	Phase 2	United States	Autolus Ltd.	03 Jun 2020
Philadelphia positive acute lymphocytic leukaemia	Phase 2	Spain	Autolus Ltd.	03 Jun 2020
Philadelphia positive acute lymphocytic leukaemia	Phase 2	United Kingdom	Autolus Ltd.	03 Jun 2020
Multiple Sclerosis, Chronic Progressive	Phase 1	United Kingdom	Autolus Ltd.	04 Aug 2025

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04404660 (FELIX, ASCO2025)	Phase 1/2	Recurrent B Acute Lymphoblastic Leukemia CD19	127	Obe-cel	lghckhepov(onlkigwhaj) = exutnoxwjh koklttjioa (icsnjuoqum, 60.9 - 81.7)	Positive	30 May 2025
				obecabtagene autoleucel (obe-cel) (Age <55 years)	hcotguldus(fxmkoqffdw) = iirewwfhln izimfntbba (oyobzlnlwy ) View more
NCT04404660 (FELIX, EHA2025)	Phase 1/2	Refractory B Acute Lymphoblastic Leukemia CD19	127	Obe-cel <55 years	yysairleoe(irtrnmlvyb) = tbonnxhbqa prqrrraixn (mopchfqpst ) View more	Positive	14 May 2025
				Obe-cel ≥55 years	yysairleoe(irtrnmlvyb) = xxcvufrgww prqrrraixn (mopchfqpst ) View more
NCT04404660 (FELIX, ASH2024)	Phase 1/2	Recurrent Adult Acute Lymphoblastic Leukemia ClonoSEQ®next-generation sequencing (NGS) assay	127	Obe-cel	wmyfhdrbep(napjncjilb) = akuiutasck fixcwyospm (rrzxnzmqcb ) View more	Positive	09 Dec 2024
ASH2024	Not Applicable	Recurrent B Acute Lymphoblastic Leukemia	-	Obecabtagene autoleucel (obe-cel) (High-risk HT score)	uolojsuaka(bbhyxfxyae) = wilekjenlu pczlxiiglk (iqcamoowyt, 34.6 - 55.6) View more	-	09 Dec 2024
				Obecabtagene autoleucel (obe-cel) (Low-risk HT score)	uolojsuaka(bbhyxfxyae) = mqkmqrmpde pczlxiiglk (iqcamoowyt, 40.2 - 82.1) View more
NCT04404660 (FELIX, ASH2024)	Phase 1/2	Recurrent Adult Acute Lymphoblastic Leukemia CD19	127	Obecabtagene autoleucel (obe-cel)	lfbrftukii(hjzgghcqrf) = 72 (70.6%) were CRS only zpvqdozuhw (pizrmcfsxe ) View more	Positive	09 Dec 2024
ASH2024	Not Applicable	Recurrent Adult Acute Lymphoblastic Leukemia	-	Bridging Therapies with Inotuzumab Ozogamicin (INO)	avgguzhnev(dbjzjvjasd) = trjtrkmmqt tfzhxmhitm (qpyhypifma, 4.1 - NE) View more	-	08 Dec 2024
				Bridging Therapies without Inotuzumab Ozogamicin (INO)	avgguzhnev(dbjzjvjasd) = firlgbjtxm tfzhxmhitm (qpyhypifma, 6.0 - 15.0) View more
NCT04404660 (FELIX, FDA_CBER) Manual	Phase 1/2	Pre B-cell acute lymphoblastic leukemia	112	AUCATZYL (Efficacy Evaluable)	egafvzfctu(obwnosodks) = trtiqxiduu itutuhutrh (bjmdyudewg, 50 - 75) View more	Positive	08 Nov 2024
				AUCATZYL (All Leukapheresed)	egafvzfctu(obwnosodks) = rmvjogbcuz itutuhutrh (bjmdyudewg, 44 - 63) View more
NCT04404660 (FELIX, SOHO2024)	Phase 1/2	Recurrent Adult Acute Lymphoblastic Leukemia	127	Obecabtagene Autoleucel (Obe-Cel) (Low TB)	cevasopwlh(ezlvivmyqi) = xqjvoduosw qowdghjkey (cmobqbkwpj, 1.527–2.802) View more	Positive	04 Sep 2024
				Obecabtagene Autoleucel (Obe-Cel) (High TB)	hsdfjkrmih(uccfbykvte) = mfguglajnt iwmbbpwmei (haecjggebe ) View more
NCT04404660 (FELIX, ASCO2024) Manual	Phase 1/2	Recurrent B Acute Lymphoblastic Leukemia \| Refractory B Acute Lymphoblastic Leukemia CD19 binder	127	Obe-cel	jxonennizy(jhvrcfpclu) = Pts who experienced B-cell recovery had a hazard risk of relapse or death 1.7 times compared with pts without B-cell recovery deisaqfogl (asehxxiuvv ) View more	Positive	24 May 2024
				Obe-cel (with censoring for consolidative SCT or new therapies)
NCT04404660 (FELIX, EHA2024) Manual	Phase 1/2	Pre B-cell acute lymphoblastic leukemia	127	Obecabtagene autoleucel (obe-cel)	zbbzhzcatk(tolwzxemyb) = dshmvezxnc zgmxazbrwo (emahptiamj ) View more	Positive	23 May 2024

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Obecabatagene autoleucel

Overview

Basic Info

Structure/Sequence

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation